Rayzebio Secures $108 Million Series C Financing To Drive Forward Its Pipeline Of Targeted Radiopharmaceuticals For Cancer
Rayzebio Secures $108 Million Series C Financing To Drive Forward Its Pipeline Of Targeted Radiopharmaceuticals For Cancer
06/15/21, 12:08 PM
Location
san diegoMoney raised
$108 million
Round Type
series c
RayzeBio, Inc., which is discovering and developing a broad pipeline of innovative targeted radiopharmaceutical drugs for cancer, today announced a $108 million Series C financing led by Venrock Healthcare Capital Partners alongside new investors Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management, and TCG X. Also participating were all of Rayze’s existing investors: venBio Partners, Versant Ventures, Samsara BioCapital, Redmile Group, Viking Global Investors, Cormorant Asset Management, OrbiMed, LifeSci Venture Partners, Logos Capital, Alexandria Venture Investments, and others.
Company Info
Location
san diego, california, united states
Additional Info
RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug binders to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed by a syndicate of sophisticated healthcare investors and was established in 2020. For additional information, please visit www.rayzebio.com